Analysis of Screen-detected Lung Cancers' Genomic Traits

N/AActive Not RecruitingNCT04204499

University College, London526 enrolled

Overview

Prospective, observational cohort study of patients undergoing surgical resection for low dose CT (LDCT) screen-detected lung cancer (detected through the SUMMIT study- ClinicalTrials.gov Identifier: NCT03934866/ lung screening programmes), in which translational research is a fundamental aspect.

The ASCENT study seeks to examine the genomic signatures of screen-detected cancers, in order to categorise the biological behaviour of such lesions and correlate this against non-invasive biological and radiological parameters. From these data, the plan is to explore strategies to characterise LDCT-detected cancers through non-invasive means, which the researchers believe may prove key in mitigating potential screening-associated harms.

Study Type

OBSERVATIONAL

Enrollment

526

Conditions

Lung Cancer

Eligibility

Sex: ALLMin age: 50 YearsMax age: 77 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Diagnosed with confirmed lung cancer or probable lung cancer via LDCT screening. 2. Planned for, or completed primary surgical resection either for histologically confirmed lung cancer, or strongly suspected lung cancer. 3. Able to provide written informed consent (or verbal informed consent for participants consenting to retrospective diagnostic samples and data collection only). Exclusion Criteria: 1. Treatment with neoadjuvant therapy for current lung malignancy as per local MDT treatment decision. 2. Known Active Human Immunodeficiency Virus (HIV), Hepatitis B virus, Hepatitis C Virus or Syphilis.

Locations (2)

St Bart's Hospital

London, United Kingdom

UCLH

London, United Kingdom

Outcomes

Primary Outcomes

Genomic exploratory research

Measuring the differences in chromosomal instability between fast- and slow-growing screen detected cancers, quantified by weighted genome integrity index (WGII) derived from whole exome sequencing (WES) data

Time frame: 4 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.